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Patients first seen with medically refractory angina1 
symptoms after saphenous vein bypass surgery pose 
a difficult problem for cardiologists and cardiovascu- 
lar surgeons. These patients are generally older, with 
more extensive, diffuse disease involving the native 
coronary arteries and venous bypass grafts. Repeat 
coronary artery bypass graft surgery (CABG) for re- 
current ischemia is technically more difficult, is asso- 
ciated with a higher mortality and morbidity, and has 
inferior long-term clinical results when compared 
with a first bypass operation.“3 Conventional balloon 
angioplasty offers an alternative mode of revascular- 
ization in selected patients. The immediate results of 
this procedure have been shown to be favorable in 
patients with discrete lesions in venous bypass grafts 
but considerably less satisfactory in diffusely dis- 
eased, ulcerated, or thrombosed venous grafts.4-6 
Furthermore, it appears that the rate of restenosis is 
high, varying from 40 % to 70 % depending on the site 
of the lesions in the graft and the overall extent of 
disease in the conduit.7-13 
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Stent implantation has been proposed as an alter- 
native or adjunct to percutaneous transluminal cor- 
onary angioplasty (PTCA) for diseased venous by- 
pass grafts. Results of early studies with small num- 
bers of patients have shown that stents can be placed 
safely and successfully in bypass grafts with an 
encouraging low rate of restenosis.14-21 Therefore we 
initiated this observational study to assess the acute 
and late results of stent implantation in stenosed 
coronary artery bypass grafts in symptomatic pa- 
tients with diffuse, extensive native coronary artery 
and bypass graft disease who are poor candidates for 
conventional balloon angioplasty or reoperation. 
METHODOLOGY 
Study population (Tables I and II). Between Janu- 
ary 1988 and March 1990, a total of 136 stents were 
implanted in 69 patients (12 women and 57 men) in 
the four participating hospitals in The Netherlands 
and Belgium. The study protocol was approved by 
the ethics committees of the individual hospitals and 
informed consent was obtained from all patients. A 
senior investigator (P. W. S.) was present for all stent 
implantations. 
The decision to implant a stent was reached after 
discussion between cardiologists and surgeons (Table 
III). Forty-two patients were considered inoperable 
because of either a high risk/benefit ratio related to 
repeat surgery (n = 28), unfavorable coronary vessel 
anatomy such as diffusely diseased distal vessels 
(n = 4), poor left ventricular function (ejection frac- 
tion <35%) (n = 6), or concurrent noncardiac risk 
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Table I. Study population 
No. of patients 
No. of bypasses 
No. of lesions 
No. of stents 
Ejection fraction (%) 
Risk factors 
Hypercholesterolemia >7 mmol/L 
Hypertension 
Smokers 
Diabetes mellitus 
69 
74 
95 
136 
53.9 (26-71) 
26 
15 
46 
14 
Table III. Reasons for preferring stent implantation (cate- 
gories are not mutually exclusive) 
Patients not suitable or high risk for repeat CABG 42 
Reasons 
High risk/benefit profile 28 
Unfavorable coronary vessel anatomy 4 
Poor left ventricular function (ejection fraction <35 % ) 6 
Concurrent noncardiac risk factors 4 
Patients considered high risk for conventional PTCA 39 
Reasons 
Long lesions (>15 mm) 32 
Tandem lesions 23 
Lesions containing ulcers 25 
Dissections 17 
Table II. Specific lesion characteristics Clot 18 
Diffusely diseased bypass graft 34 
No. of bypasses 
Age of bypass graft (mo) 
Mean diameter of graft (mm) 
Mean minimal lumen diameter (mm) 
Length of stenosis (mm) 
74 
83 (l-166) 
3.3 (1.6-7.0) 
1.4 (O-2.9) 
16.5 (2-50) 
Eccentric lesions 
Table IV. Stent implantation data 
No. of stents 
Mean diameter of stent (mm) 
53 
136 
4.3 (3.5-6.0) 
factors (n = 4). Conventional coronary angioplasty 
was considered high risk in 39 patients because of the 
age of the grafts, the length of the stenosis, and/or 
unfavorable angiographic features (tandem lesions, 
eccentric lesions, lesions containing ulcers, aneu- 
rysms, calcifications, or dissections) (Figs. 1 to 4). 
The mean age of the patients was 63 years (range 
44 to 78), and the mean age of the implanted bypass 
grafts was 83 months (range 1 to 166). Forty-eight 
patients had at least one previous myocardial infarc- 
tion, and eight had undergone more than one previ- 
ous bypass procedure. Single-, double-, and triple- 
vessel disease was present in 3 % , 23 % , and 74 % of 
the patients, respectively. Eleven patients were in 
New York Heart Association (NYHA) class II, 27 
were in class III, and 29 were in class IV; in two pa- 
tients the stents were implanted during evolving my- 
ocardial infarction. All patients had documented 
ECG evidence of ischemia. 
The stent implantation data are presented in Ta- 
ble IV. A single stent was implanted in 30 patients, 
two stents in 24 patients, three stents in seven 
patients, four stents in five patients, five stents in one 
patient, and 6 stents in two patients. The stent was 
placed in single grafts in 25 patients and in sequen- 
tial grafts in 44. In five patients the stent was 
implanted into totally occluded vessels (during an 
evolving myocardial infarction in two and in chronic 
occlusions in three. 
Implanted device. In the first 26 patients we used 
the Medinvent Wallstent (Medinvent, Lausanne, 
Position 
Ostial 
Shaft 
Distal anastomosis 
Procedure type 
Single stent-single lesion 
Multiple stent-single lesion 
Multiple stent-multiple lesion 
7 
127 
4 
30 
90 
16 
Switzerland), and later we used the polymer-coated 
Medinvent Biogold stent. The stent consists of a 
stainless steel alloy with a self-expanding mesh 
design. I5 The unconstrained length varied between 
15 and 27 mm, and its diameter in the fully expanded 
state was between 3.5 and 6.0 mm and was selected 
to be 0.50 mm larger than the reference diameter of 
the vessel. 
After stent implantation the patients were moni- 
tored in the coronary care unit. The rigorous antico- 
agulation regimen has been described previously.22 
All patients received aspirin the day before the pro- 
cedure and intravenous heparin (10,000 IU) at the 
beginning of the procedure. Before stent implanta- 
tion 10,000 IU heparin and 500 mg dextran every 4 
hours were given intravenously. Immediately after 
stent implantation 100,000 to 250,000 IU urokinase 
was infused into the coronary bypass graft via the 
guiding catheter. Intravenous heparin administra- 
tion was continued at a minimum dosage of 24,000 
IU/24 hours; the dosage was adjusted according to 
the activated partial thromboplastin time (80 to 120 
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Fig. 1. Jump graft to left anterior descending artery (ar- 
row), then to first diagonal branch, and then to marginal 
branch. A, Two lesions in jump graft between diagonal and 
marginal branches (arrowheads). B, Immediate result af- 
ter stenting. Distal end of stent may have extended into 
native coronary artery. 
seconds). Oral acenocoumarol was started on the day 
of implantation. The heparin infusion was continued 
until the prothrombin time measured by throm- 
botest (Nycomed, Oslo, Norway) was lowered to 5% 
to 10% for 2 subsequent days and discontinued 
slowly thereafter. After stent implantation the pa- 
tients were also given aspirin (300 mg/day), dipy- 
ridamole (300 to 450 mg/day), and nifedipine (30 to 
60 mg/day), which in addition to the oral anticoagu- 
lant were maintained for 3 to 6 months after the pro- 
Fig. 2. Top panel, Two tandem lesions with aneurysm of 
bypass graft located proximal to first lesion. Second panel, 
Balloon angioplasty catheter in position across lesion. Bal- 
loon dilatation resulted in dissection. Third panel, After 
implantation of distal stent, intraluminal flap (arrow) is 
still evident in proximal lesion. Lower panel, After im- 
plantation of second stent in proximal lesion. 
cedure. The patients were followed at our outpatient 
clinic at 1 and 3 months and underwent repeat cor- 
onary angiography 6 months after the initial proce- 
dure or earlier if symptoms recurred. 
Quantitative coronary angiography. The quantita- 
tive analysis of the stenotic coronary segments was 
carried out with the computer-assisted Cardiovascu- 
lar Angiography Analysis System (CAAS), which has 
been described in detai1.23-28 The angiographic anal- 
ysis was done before and after angioplasty, immedi- 
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Fig. 3. A, Bypass graft to right coronary artery (7-&h image intensifier). Long segment bypass vessel is 
severely diseased with involvement of ostium and several complex features including ulceration in prox- 
imal aspect of graft (arrow) and intraluminal defect in midgraft (arrowhead). 6, After placement of three 
stents (s-inch image intensifier). C, Six-month follow-up angiogram showing late excellent result. 
ately after stent implantation, and at follow-up in all 
patients with the average of multiple matched views 
with orthogonal projections wherever possible. 
Restenosis. Two different sets of criteria were ap- 
plied to determine the rate of restenosis. We have 
found a change in minimal luminal diameter of 0.72 
mm or more to be a reliable indicator of angiographic 
progression of vessel narrowing.23-25 This value takes 
into account the limitations of coronary angiographic 
measurements and represents two times the long- 
term variability for repeat measurements of a coro- 
nary obstruction by means of the CAAS. The other 
criterion for restenosis was an increase in the diam- 
eter of the stenosis (DS) from less than 50% after 
stent implantation to more than or equal to 50% at 
follow-up. This criterion was selected according to 
common clinical practice.“g 
OBSERVATIONS 
Stent implantation procedure. All patients under- 
went successful stent implantation (DS -30% im- 
mediately after placement of the stent). In two 
patients the initial stent was not optimally positioned 
and did not cover the entire lesion, so that an addi- 
tional procedure was required to implant another 
stent to achieve an optimal result. Although no im- 
mediate major complications occurred during the 
procedure, two patients required intracoronary 
thrombolytic therapy because of distal embolization 
without subsequent elevation of the creatine kinase 
level. Three other patients had increases in the cre- 
atine kinase level (<200 IU). 
In-hospital complications. Acute thrombotic events 
in the stent occurred in seven patients (10 % ). One of 
these occlusions was related to cessation of anticoag- 
ulation treatment. This patient (considered inopera- 
ble) had a severe retroperitoneal hematoma 7 days 
after stent implantation, which necessitated discon- 
tinuation of the anticoagulation therapy. Thirty days 
after implantation the patient had an acute myocar- 
dial infarction, leading to cardiogenic shock and 
death. One patient, who had the stent implanted 
during an evolving myocardial infarction, had an 
acute thrombotic closure of the stented vessel 1 day 
after stent implantation. The resulting myocardial 
infarction was treated conservatively. 
Two other patients, who had unstable angina pec- 
toris and angiographic defects consistent with 
thrombi, had acute thrombotic occlusions and myo- 
cardial infarctions 7 and 12 days after stent implan- 
tation, respectively. One of these patients, who was 
treated conservatively, died suddenly 6 months after 
implantation, having remained stable with mild an- 
gina pectoris. The other patient underwent CABG 
after emergent reopening of the vessel during repeat 
PTCA. The last thrombotic occlusion occurred 1 day 
after implantation in one of the patients with stent 
implantation after recanalization of a chronically oc- 
cluded graft. This patient was referred for repeat 
CABG. 
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Fig. 4. A, Complex lesion with ulceration (arrow) in jump bypass graft before stenting. B, Immediate re- 
sult after stenting. C, Six-month follow-up angiogram showing restenosis within stent. Outline of stent is 
faintly visible. 
Two patients had unstable angina pectoris 3 and 10 
days after stent implantation, which was related to an 
angiographically visible but nonocclusive thrombus. 
In one patient this thrombus was related to cessation 
of anticoagulation 6 days after the procedure as a re- 
sult of Mallory-Weiss syndrome with persistent gas- 
trointestinal bleeding. 3o Because of symptomatic re- 
current ischemia, the patient was sent for surgery. 
The second patient, who had been treated for unsta- 
ble angina pectoris, had resting angina pectoris 1 day 
after implantation of two stents. Angiography re- 
vealed a partially occlusive thrombus between the 
two stents and another stent was placed between the 
two previous stents. The following day resting angina 
pectoris recurred and the patient was treated surgi- 
cally. 
Bleeding complications occurred in 23 patients 
(33 9% ). Two patients had fatal intracranial bleeding, 
one patient had a retroperitoneal hematoma, and two 
patients had gastric bleeding. An additional 18 pa- 
tients had hematomas at puncture sites requiring 
blood transfusions, and seven of these patients re- 
quired surgical repair of a false aneurysm. Bleeding 
complications were associated with a considerably 
longer hospital stay-18 days in comparison to 7 days 
when the postimplantation course was uneventful. 
Discharge status. Sent implantation resulted in 
complete relief of angina pectoris (NYHA class I) in 
45 patients (64 % ). Ten patients (14 5% ) still had mild 
symptoms (NYHA class II) after stent implantation 
(NYHA class II), and five patients (7 % ) remained in 
NYHA class III. Four of these patients were consid- 
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ered inoperable and the fifth was referred for reoper- 
ation. 
Long-term follow-up 
Angiography. In 53 (90%) of the 59 patients with 
successful stenting and no major in-hospital compli- 
cations, follow-up angiography was performed at 
4.9 +- 3.4 months. Of the remaining six patients 
without angiographic follow-up, five refused to un- 
dergo control angiography, and in another patient 
the implantation film was technically inadequate for 
analysis, although no significant restenosis was seen 
at follow-up. 
In the overall group the mean minimal luminal di- 
ameter increased significantly from 1.4 f 0.82 to 
2.7 + 0.7 mm (p < 0.001) and the diameter stenosis 
decreased significantly from 58 f 15 % to 24 + 9 % . 
However, at late follow-up (including occlusions) 
there was a significant reduction in the mean minimal 
luminal diameter to 1.9 i 1.1 mm @ < 0.001) and a 
significant increase in the diameter of the stenosis to 
43 +- 30% (p < 0.001). 
The incidence of restenosis depended on the def- 
inition. According to the criterion of a change in 
minimal luminal diameter of 0.72 mm, detectable 
angiographic narrowing occurred within the stent in 
25 patients (47 % ). An increase in the diameter of the 
stenosis to 50% at follow-up was seen in 21 patients 
(40 % ) and immediately adjacent to the stent in four 
patients (7 % ). Stent occlusion was found in three of 
these patients. 
Clinical follow-up. In the group of patients with 
angiographic restenosis (diameter stenosis >50 % 
criterion) (n = 25), 19 patients had a recurrence of 
angina pectoris necessitating reintervention (repeat 
PTCA, n = 10; atherectomy, n = 2; repeat CABG, 
n = 7). Three of the patients who underwent surgery 
died during the postoperative period. 
In the group without restenosis (n = 28), 15 pa- 
tients had a recurrence of significant angina pectoris 
within 1 to 24 months after stent implantation. Ten 
patients underwent further intervention. In six a 
second stent was implanted in either the same or an- 
other bypass graft. Three patients underwent PTCA 
of one or more native vessels and one patient had re- 
peat bypass surgery. The five remaining patients 
were treated medically. One patient without signifi- 
cant restenosis at the 6-month angiography died 
suddenly 500 days after stent implantation. 
COMMENTS 
The management of recurrent ischemia in patients 
who have had previous bypass surgery presents a se- 
rious and growing problem. Symptoms of myocardial 
ischemia recur or progress in approximately 5% of 
patients per year,3* 26, 27 and after 5 years up to 25% 
of vein grafts are occluded and 25% may show 
stenoses greater than 70% .28 Reoperation is techni- 
cally more complicated to perform and is generally 
associated with a higher mortality and morbidity 
than a primary operation and achieves symptomatic 
relief in only 60% to 70 % of patients as compared 
with the 80 % to 90 7, success rate after primary op- 
erations. The perioperative myocardial infarction 
rate varies among surgical groups between 2.0 % and 
11.5%. The mortality rate after repeat bypass sur- 
gery ranges from 1.2% to 12.5% .lw3 Conventional 
balloon angioplasty has reported angiographic suc- 
cess rates of 75 % to 100 % for bypass grafts,7-13 with 
complications rates similar to angioplasty in native 
vessels. However, restenosis appears to occur more 
frequently with rates as high as 46% reported for 
proximal sites.24, 27 
The majority of our patients were considered high 
risk for surgery or repeat PTCA. Inasmuch as all of 
these patients had severe symptoms in spite of max- 
imal medical therapy, it was decided to try to attempt 
stenting of the angina-related bypass graft, although 
in some cases it was clear that full relief could not be 
expected because of diffuse native vessel disease that 
prohibited additional intervention. Most of the pro- 
cedures were done without surgical standby. Since 
the introduction of stenting of stenosed saphenous 
bypass grafts in our institution in 1988, a total of 69 
patients have been treated successfully with this new 
intervention compared with only 84 patients who 
underwent conventional angioplasty for stenosed sa- 
phenous bypass grafts during the period 1980 to 1988. 
This new treatment modality has significantly ex- 
panded our therapeutic options in this particular pa- 
tient group. 
Our results show that stenting bypass grafts is 
technically feasible with excellent immediate results. 
Two advantages of the Wallstent for use in bypass 
grafts are (1) the length of the stent can be selected 
up to 25 mm for long lesions and (2) the self-expand- 
ing property appears to be an effective splint to tack 
back friable, protuberant atheromatous material and 
minimize embolization into the native coronary cir- 
culation. In 30 patients the stent was implanted di- 
rectly without prior balloon dilatation for lesions that 
appeared high risk for embolization. No increase in 
creatine kinase levels was documented in this group 
of procedures. 
Several important lessons emerge from this study. 
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First, the majority of stent occlusions occurred in 
patients with acute ischemic syndromes (myocardial 
infarction or unstable angina pectoris with angio- 
graphic evidence of thrombi). The combination of 
thrombi during evolving myocardial infarction and 
unstable angina and the implantation of intracoro- 
nary stents seems to be highly thrombogenic leading 
to further thrombus formation and acute occlusion of 
the stent. Therefore we now carefully select our pa- 
tients and when the diagnostic angiogram suggests 
the presence of intravascular clots, the patients are 
treated with intravenous heparin (25,000 IU/24 hr) 
for 1 week before stent implantation. Although 
improved patient selection should decrease the oc- 
currence of acute stent closure, it will remain an un- 
predictable event as evidenced by stent occlusion in 
one patient who was optimally anticoagulated and 
without the previously described risk factors. Fur- 
thermore, the timing of stent occlusion is also unpre- 
dictable (between 2 and 12 days), which complicates 
discharge planning decisions. Second, a meticulous 
anticoagulation schedule must be followed with fre- 
quent monitoring to minimize bleeding complica- 
tions. As our experience evolved, bleeding and occlu- 
sion problems were encountered much less frequently 
and as a result, sulphinpyrazone was withdrawn be- 
cause of a lack of evidence of its efficacy in the pre- 
vention of acute closure. Special care must also be 
given to insertion and removal of the femoral arterial 
sheath, since this accounted for the majority of 
bleeding complications. In particular, removal of the 
sheath >12 hours after implantation was associated 
with increased vascular complications. During the 
last 15 stent implantation procedures, no throm- 
bolytic agents were administered leading to a con- 
siderable decrease in bleeding problems in the groin. 
Furthermore, oral coumadin was started the day be- 
fore stent implantation leading to a quicker optimal- 
ization of the oral anticoagulation therapy, which 
made a shorter hospital stay possible. 
The stent-related restenosis rate (47%) seems to 
be comparable to that in historical studies of con- 
ventional angioplasty in venous coronary bypass 
grafts.4, 5* 3o However, these comparisons may not be 
valid since our population consisted of patients who 
were less than suitable candidates for conventional 
angioplasty. Earlier reports from Lausanne sug- 
gested a much lower restenosis rate (9%) in lesions 
implanted with the Medinvent stent in bypass 
grafts.171 32 However, these differences may be the re- 
sult of either differences in selection criteria, meth- 
ods of angiographic assessment (quantitative vs vi- 
sual estimation), or both. 
Frequent reintervention in our study group was 
required because of restenosis or progression of dis- 
ease in other lesions, a problem similar to that 
encountered with conventional angioplasty in bypass 
grafts. Three recent reports have been published on 
the late clinical follow-up of patients with conven- 
tional angioplasty in bypass grafts. The Thorax- 
center reported that only 41% of patients were alive 
and event free (myocardial infarction, repeat CABG, 
repeat PTCA) at a median follow-up period of 2.1 
years.4 A review of the overall Dutch experience also 
showed limited late beneficial results with 2-year and 
five-year event-free survival rates of 5270 and 26%) 
respectively, in 454 bypass patients.5 Webb et al.“l 
have described a 71% freedom from death, infarc- 
tion, and surgery at 5 years in bypass patients who 
underwent PTCA at their institution but did not in- 
clude the 27% incidence of second angioplasty pro- 
cedures also required in their patient group. It is clear 
that stenting and angioplasty are only short-term so- 
lutions and do not affect the underlying problems of 
progressive graft atherosclerosis and iatrogenically 
induced restenosis. 
Conclusions. Patients with severe coronary artery 
disease and previous bypass surgery who have. re- 
fractory symptoms as a result of progression of dis- 
ease in the bypass graft comprise a difficult challenge 
to the physician. In patients who are poor surgical 
risks and unsuitable candidates for balloon angio- 
plasty because of unfavorable anatomy, coronary 
stenting with the Wallstent can be performed suc- 
cessfully and offers an alternative therapy. However, 
stent implantation remains complicated by acute 
thrombotic occlusion and bleeding complications as- 
sociated with the intense anticoagulation. The early 
benefits of stenting may be mitigated by the progres- 
sion of disease in bypass grafts and iatrogenic in- 
duced restenosis. Stenting should be considered a 
palliative procedure in medically refractory patients 
with coronary bypass graft disease. 
SUMMARY 
During a Z-year period, 136 self-expanding Wall- 
stents were implanted in saphenous vein bypass 
grafts in 69 patients with end-stage coronary artery 
disease. All patients had severe symptoms and the 
majority were poor candidates for either repeat sur- 
gery or conventional bypass coronary angioplasty 
because of unfavorable native anatomy, impaired left 
ventricular function, or a high-risk bypass lesion 
anatomy for coronary angioplasty. All procedures 
were technically successful without major complica- 
tions and a need for emergency bypass surgery. 
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However, during the hospital stay acute thrombotic 
complications occurred in seven patients (10%) re- 
sulting in one death and acute myocardial infarction 
in five patients and necessitating emergency repeat 
PTCA in two patients and repeat CABG in four. 
Twenty-three patients had serious hemorrhagic com- 
plications directly related to the rigorous anticoagu- 
lation schedule. Two patients died of fatal cerebral 
bleeding. During follow-up, another five patients 
died accounting for a total mortality rate of 12 % . At 
late angiographic follow-up (4.9 + 3.4 months, 
n = 53), 25 patients (47%) had a restenosis (~50% 
DS) within or immediately adjacent to the stent, ne- 
cessitating reintervention in 19 patients (PTCA, 
n = 12; repeat CABG, n = 7). In the group without 
stent-related restenosis (n = 28), 15 patients had 
progression of disease in either the native or bypass 
vessels leading to recurrence of major angina1 symp- 
toms within 1 to 24 months. Ten of these patients re- 
quired further intervention (stent, n = 6; PTCA, 
n = 3; repeat CABG, n = 1). Stenting in saphenous 
coronary bypass grafts can be performed safely with 
excellent immediate angiographic and clinical re- 
sults. Early occlusion, late restenosis, and bleeding 
complications associated with the aggressive antico- 
agulant treatment remain significant limitations. 
Reintervention as a result of restenosis or progression 
of disease in other lesions is common. Stenting of 
diseased bypass grafts in symptomatic patients with 
end-stage coronary artery disease (who are at high 
risk for conventional angioplasty or surgical reinter- 
vention) may be useful as palliative therapy. 
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